Humasis Co

Humasis Co Financing Cash Flow

The Net Financing Cash Flow of Humasis Co (205470.KQ) as of Oct 27, 2026 is -28.90 B KRW. In the previous year, Net Financing Cash Flow was -5.93 B KRW — a change of 387.45% (lower).

Financing Cash Flow

-28.90 BKRW

YoY

387.45%

Last updated:

Net Financing Cash Flow of Humasis Co is 2024 -28.90 B KRW. Net Financing Cash Flow of Humasis Co was 2023 -5.93 B KRW. It decreases by 387.45% lower compared to the previous year.

The Humasis Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
13.72 B KRW
Jan 1, 2018
7.00 B KRW
Jan 1, 2019
2.68 B KRW
Jan 1, 2020
2.68 B KRW
Jan 1, 2021
-12.05 B KRW
Jan 1, 2022
-37.39 B KRW
Jan 1, 2023
-5.93 B KRW
Jan 1, 2024
-28.90 B KRW
The Humasis Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
-28.90 BKRW+387.45%
-5.93 BKRW-84.14%
-37.39 BKRW+210.23%
-12.05 BKRW-550.09%
2.68 BKRW0.00%
2.68 BKRW-61.73%
7.00 BKRW-49.01%
13.72 BKRW+495.68%
2.30 BKRW0.00%
2.30 BKRW-95.93%
56.61 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Net Financing Cash Flow of Humasis Co is -28.90 B KRW in 2024.

Net Financing Cash Flow of Humasis Co changed from -5.93 B KRW to -28.90 B KRW, representing a 387.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co